Mechanism
Ipamorelin is a synthetic pentapeptide developed as the first selective growth-hormone secretagogue. It mimics ghrelin at the pituitary and hypothalamus but, unlike earlier GHRPs, does so without meaningfully stirring the stress-hormone axis.
| Mechanism | Detail |
|---|---|
| GHS-R1a agonism | Binds and activates the ghrelin receptor on pituitary somatotrophs and in the hypothalamus, triggering a pulsatile release of stored growth hormone. |
| Selectivity | At GH-releasing doses it produces little to no rise in ACTH, cortisol, or prolactin — the feature that distinguishes it from GHRP-2, GHRP-6, and hexarelin. |
| Pulse amplification | Works with (not against) endogenous GHRH; often paired with a GHRH analog such as CJC-1295 or sermorelin to amplify the natural GH pulse rather than override feedback. |
| Downstream IGF-1 | GH released in response acts on the liver and peripheral tissues to raise IGF-1, the mediator most GH effects are attributed to. |
Evidence Summary
Ipamorelin has a deeper evidence trail than most research peptides: a clear preclinical pharmacology record plus registered human trials. What it lacks is a completed, positive efficacy program for any anti-aging or body-composition use.
| Research Area | Evidence | Study Type | Notes |
|---|---|---|---|
| GH release & selectivity | GH spikes, minimal cortisol/prolactin | Preclinical + human PK | The selectivity claim is well replicated in animal and early human pharmacology. |
| Bone / body composition | Animal bone & lean-mass signals | Preclinical | Plausible via the GH/IGF-1 axis; not confirmed in controlled human outcome trials. |
| GI motility | Prokinetic effect on gut | Preclinical + Phase 2 | The basis for its clinical development in postoperative ileus. |
| Anti-aging / recovery claims | No controlled human trials | Anecdotal | The most-marketed uses are also the least supported. |
| Human clinical trials | Reached Phase 2 (postoperative ileus) | Phase 2 | Gave it a modest human PK and safety base, but the program did not yield an approved product. |
Divergence — What This Means
How far does community use diverge from the science?
Moderate — and notably lower than most peptides in this class. Because Ipamorelin actually went through Phase 2 trials, there is a real human dose window (roughly 200–300 mcg) that overlaps with how the community uses it, so injected amounts are not wildly off-label in magnitude.
The divergence is mostly in purpose and duration: trials studied short-term GI motility and safety, while community use targets long-run body composition, recovery, and anti-aging — goals no completed trial has validated. Chronic daily dosing over months is also beyond anything the human data covers.
The divergence is mostly in purpose and duration: trials studied short-term GI motility and safety, while community use targets long-run body composition, recovery, and anti-aging — goals no completed trial has validated. Chronic daily dosing over months is also beyond anything the human data covers.
Dose Reference
Not medical advice. Not instruction for human use. For reference only.
Common dose
200–300 mcg
per injection, SC (community-reported)
Frequency
1–3× daily
often pre-sleep and/or fasted
Stacking
+ CJC-1295
frequently paired with a GHRH analog
Timing
Away from food
to avoid blunting the GH pulse
Figures are community and anecdotal conventions, not medical guidance. Ipamorelin is sold research-use-only and is not approved for human use. Nothing here is a recommendation to dose.
Safety Profile
Ipamorelin’s selectivity gives it a relatively clean short-term profile in the human data that exists, but that data is short-term and narrow. Long-run and repeated-use safety in the way the community uses it has not been established.
Animal / preclinical — signals observed
Injection-site reactions (redness, itching)
Headache, flushing, or lightheadedness
Transient increase in appetite (usually milder than GHRP-6)
Water retention or tingling, consistent with raised GH/IGF-1
What is not known (human)
Effects of chronic daily use over months to years
Long-term consequences of sustained elevated GH/IGF-1
Interaction with pre-existing endocrine or metabolic conditions
Purity and dosing accuracy of gray-market research-grade material
Absence of reported harm in short trials is not the same as proven long-term safety. This is not medical advice.
Regulatory Status — Updated July 2026
Named for reconsideration, but not yet reviewed
Ipamorelin was not part of the July 23–24, 2026 PCAC meeting and has not been formally reviewed or voted on. It was named among the peptides HHS flagged for reconsideration in early 2026, but that review is still pending a future round. It remains unapproved by the FDA and is sold research-use-only. Track current status →
Where to Source
Source research-grade Ipamorelin
Lone Star Peptide Co. — Houston, TX. Batch-specific COAs on every vial, same-day domestic shipping, and third-party testing. The most transparent way to source Ipamorelin.
Peptide Atlas is created by Lone Star Peptide Co. — a disclosed placement. Full disclosure.
Frequently Asked Questions
No. Ipamorelin was not on the agenda for the July 23–24, 2026 PCAC meeting and was not reviewed or voted on. It was flagged by HHS for possible reconsideration earlier in 2026, but that remains pending a future round. It is currently still sold research-use-only.
At doses that release growth hormone, it produces little to no rise in cortisol, ACTH, or prolactin — unlike older GHRPs such as GHRP-2 and GHRP-6. That cleaner hormonal profile is its main selling point.
Yes, more than most research peptides. It reached Phase 2 human trials (for postoperative ileus / GI motility), giving it a modest human pharmacokinetic and short-term safety base. However, no completed trial validates the body-composition or anti-aging uses it is marketed for.
Ipamorelin (a ghrelin-receptor agonist) and CJC-1295 (a GHRH analog) act through complementary pathways, so combining them tends to produce a larger GH pulse than either alone. This is a community convention, not an approved protocol.
Compare Ipamorelin